<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33060431</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-712X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
              <Season>Nov/Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical psychopharmacology</Title>
          <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Quetiapine-Associated Rhabdomyolysis: A Case Report and Literature Review.</ArticleTitle>
        <Pagination>
          <StartPage>619</StartPage>
          <EndPage>624</EndPage>
          <MedlinePgn>619-624</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001292</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yimeng</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Weidi</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chuanyue</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bo</LastName>
            <ForeName>Qijing</ForeName>
            <Initials>Q</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8109496</NlmUniqueID>
        <ISSNLinking>0271-0749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012206" MajorTopicYN="N">Rhabdomyolysis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33060431</ArticleId>
        <ArticleId IdType="doi">10.1097/JCP.0000000000001292</ArticleId>
        <ArticleId IdType="pii">00004714-202011000-00018</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Halfdanarson O, Zoega H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27:1064–1076.</Citation>
        </Reference>
        <Reference>
          <Citation>Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20:135.</Citation>
        </Reference>
        <Reference>
          <Citation>Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15:58–69.</Citation>
        </Reference>
        <Reference>
          <Citation>Linares LA, Golomb BA, Jaojoco JA, et al. The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening. Curr Drug Saf. 2009;4:181–187.</Citation>
        </Reference>
        <Reference>
          <Citation>Packard K, Price P, Hanson A. Antipsychotic use and the risk of rhabdomyolysis. J Pharm Pract. 2014;27:501–512.</Citation>
        </Reference>
        <Reference>
          <Citation>Laoutidis ZG, Kioulos KT. Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology (Berl). 2014;231:4255–4270.</Citation>
        </Reference>
        <Reference>
          <Citation>Luetmer MT, Boettcher BJ, Franco JM, et al. Exertional rhabdomyolysis: a retrospective population-based study. Med Sci Sports Exerc. 2020;52:608–615.</Citation>
        </Reference>
        <Reference>
          <Citation>Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017;135:398–408.</Citation>
        </Reference>
        <Reference>
          <Citation>Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10:721–746.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith RP, Puckett BN, Crawford J, et al. Quetiapine overdose and severe rhabdomyolysis. J Clin Psychopharmacol. 2004;24:343.</Citation>
        </Reference>
        <Reference>
          <Citation>Plesnicar BK, Lasic JK, Plesnicar A. Quetiapine and elevated creatine phosphokinase (CK). Pharmacopsychiatry. 2007;40:203–204.</Citation>
        </Reference>
        <Reference>
          <Citation>Dickmann JR, Dickmann LM. An uncommonly recognized cause of rhabdomyolysis after quetiapine intoxication. Am J Emerg Med. 2010;28:1060.e1–1060.e1062.</Citation>
        </Reference>
        <Reference>
          <Citation>Liolios A, Sentissi O. Rhabdomyolysis following acute extended-release quetiapine poisoning: a case report. Case Rep Psychiatry. 2012;2012:347421.</Citation>
        </Reference>
        <Reference>
          <Citation>Akinci E, Köylü R, Akilli NB, et al. Rhabdomyolysis secondary to quetiapine and olanzapine intoxication. Akademik Acil Tip Olgu Sunumlari Dergisi. 2014;5:87–89.</Citation>
        </Reference>
        <Reference>
          <Citation>Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl). 2000;150:347–348.</Citation>
        </Reference>
        <Reference>
          <Citation>Apikoglu Rabus S, Izzettin F, Rabus M, et al. Severe creatine kinase increase during quetiapine and mirtazapine treatment. Psychopharmacology (Berl). 2006;185:263–264.</Citation>
        </Reference>
        <Reference>
          <Citation>Himmerich H, Ehrlinger M, Hackenberg M, et al. Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. J Clin Psychopharmacol. 2006;26:676–677.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein JP, Fiedler U, Appel H, et al. Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry. 2006;39:39–40.</Citation>
        </Reference>
        <Reference>
          <Citation>Jahn H, Kiefer F, Arlt J. Rhabdomyolysis with quetiapine. Ger J Psychiatry. 2008;11:79–80.</Citation>
        </Reference>
        <Reference>
          <Citation>Stephani C, Trenkwalder C. Rhabdomyolysis after low-dose quetiapine in a patient with Parkinson's disease with drug-induced psychosis: a case report. Mov Disord. 2010;25:790–791.</Citation>
        </Reference>
        <Reference>
          <Citation>Ceri M, Unverdi S, Altay M, et al. Comment on: low-dose quetiapine-induced severe rhabdomyolysis. Ren Fail. 2011;33:463–464.</Citation>
        </Reference>
        <Reference>
          <Citation>Velasco-Montes J, Orinuela-Gonzalez I, Sanjuan-Lopez AZ. Rhabdomyolysis secondary to quetiapine. Actas Esp Psiquiatr. 2012;40:97–99.</Citation>
        </Reference>
        <Reference>
          <Citation>Aggarwal R, Guanci N, Marambage K, et al. A patient with multiple episodes of rhabdomyolysis induced by different neuroleptics. Psychosomatics. 2014;55:404–408.</Citation>
        </Reference>
        <Reference>
          <Citation>Keskin M, Ceylan G, Karaca M, et al. A serious rhabdomyolysis associated with the use of quetiapine: case report. Turkiye Klinikleri Pediatri. 2015;24:32–36.</Citation>
        </Reference>
        <Reference>
          <Citation>Restrepo D, Montoya P, Giraldo L, et al. Rhabdomyolysis in a bipolar adolescent. Analysis of associated factors. Rev Colomb Psiquiatr. 2015;44:183–188.</Citation>
        </Reference>
        <Reference>
          <Citation>Ansari J, Anwar S. Quetiapine use resulting in severe rhabdomyolysis: a rare adverse effect. Int J Int Med. 2016;12.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu J, Wei Y. Rhabdomyolysis caused by quetiapine: a case report. Chin J Pharmacoepidemiol (Chinese). 2017;26:721–722.</Citation>
        </Reference>
        <Reference>
          <Citation>Bach P, Koopmann A, Hermann D, et al. Massive creatine kinase elevation in 2 patients during short-term and low-dose antipsychotic monotherapy with quetiapine. J Clin Psychopharmacol. 2018;38:385–387.</Citation>
        </Reference>
        <Reference>
          <Citation>Saguin E, Keou S, Ratnam C, et al. Severe rhabdomyolysis induced by quetiapine and mirtazapine in a French military soldier. J R Army Med Corps. 2018;164:127–129.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhuang H, Liu S, Du H, et al. Quetiapine-induced severe elevation of creatine kinase: a case report. China Pharm (Chinese). 2019;22:702–704.</Citation>
        </Reference>
        <Reference>
          <Citation>Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 1996;15:395–405.</Citation>
        </Reference>
        <Reference>
          <Citation>Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?Psychopharmacology (Berl). 2000;150:349–350.</Citation>
        </Reference>
        <Reference>
          <Citation>Masi G, Milone A, Viglione V, et al. Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature. J Child Adolesc Psychopharmacol. 2014;24:536–542.</Citation>
        </Reference>
        <Reference>
          <Citation>Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013;65:779–808.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen LC, Bai YM, Chang MH. Polydipsia, hyponatremia and rhabdomyolysis in schizophrenia: a case report. World J Psychiatry. 2014;4:150–152.</Citation>
        </Reference>
        <Reference>
          <Citation>Cao GY, Wang CG, Chen MH, et al. Rhabdomyolysis after antipsychotic use: case reports and literature review. Chin Pharm J (Chinese). 2019;54:1527–1533.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
